{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vilanterol", "query": { "intervention": "Vilanterol" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 59, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vilanterol&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T00:30:18.342Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01573624", "title": "Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "FF/GSK573719", "type": "DRUG" }, { "name": "FF", "type": "DRUG" }, { "name": "FF/VI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 421, "start_date": "2012-04-03", "completion_date": "2013-02-04", "has_results": true, "last_update_posted_date": "2017-10-06", "last_synced_at": "2026-09-04T00:30:18.342Z", "location_count": 4, "location_summary": "St Louis, Missouri • Medford, Oregon • Orangeburg, South Carolina + 1 more", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Medford", "state": "Oregon" }, { "city": "Orangeburg", "state": "South Carolina" }, { "city": "Spartanburg", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01573624" }, { "nct_id": "NCT02487446", "title": "Efficacy and Safety Study of QVA149 in COPD Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "QVA149", "type": "DRUG" }, { "name": "Umeclidinium/vilanterol", "type": "DRUG" }, { "name": "Placebo (umeclidinium/vilanterol)", "type": "DRUG" }, { "name": "Placebo (QVA149)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 357, "start_date": "2015-07-28", "completion_date": "2016-09-12", "has_results": true, "last_update_posted_date": "2017-12-26", "last_synced_at": "2026-09-04T00:30:18.342Z", "location_count": 58, "location_summary": "Andalusia, Alabama • Anniston, Alabama • Jasper, Alabama + 52 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Anniston", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" }, { "city": "Multiple Locations", "state": "Alabama" }, { "city": "Multiple Locations", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02487446" }, { "nct_id": "NCT05062304", "title": "Replication of the IMPACT COPD Trial in Healthcare Claims Data", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "COPD" ], "interventions": [ { "name": "Fluticasone Furoate-Vilanterol Trifenatate", "type": "DRUG" }, { "name": "Furoate-umeclidinium-vilanterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "40 Years to 120 Years" }, "enrollment_count": 17281, "start_date": "2020-12-13", "completion_date": "2021-07-22", "has_results": false, "last_update_posted_date": "2023-07-27", "last_synced_at": "2026-09-04T00:30:18.342Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05062304" }, { "nct_id": "NCT02164539", "title": "Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "FF", "type": "DRUG" }, { "name": "UMEC", "type": "DRUG" }, { "name": "VI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 338, "start_date": "2014-07-01", "completion_date": "2015-07-18", "has_results": true, "last_update_posted_date": "2017-10-11", "last_synced_at": "2026-09-04T00:30:18.342Z", "location_count": 14, "location_summary": "Newport Beach, California • San Diego, California • Upland, California + 11 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Sunset", "state": "Louisiana" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02164539" }, { "nct_id": "NCT02730351", "title": "Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Fluticasone furoate/ Vilanterol 100 mcg/25 mcg", "type": "DRUG" }, { "name": "Fluticasone propionate 250 mcg", "type": "DRUG" }, { "name": "Placebo via ELLIPTA inhaler", "type": "DRUG" }, { "name": "Placebo via DISKUS / ACCUHALER", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "12 Years to 50 Years" }, "enrollment_count": 75, "start_date": "2016-05-25", "completion_date": "2017-02-03", "has_results": true, "last_update_posted_date": "2019-07-16", "last_synced_at": "2026-09-04T00:30:18.342Z", "location_count": 13, "location_summary": "Huntington Beach, California • Los Angeles, California • San Diego, California + 9 more", "locations": [ { "city": "Huntington Beach", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02730351" }, { "nct_id": "NCT01316900", "title": "24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "GSK573719/GW642444 125/25", "type": "DRUG" }, { "name": "GSK573719/GW642444 62.5/25", "type": "DRUG" }, { "name": "GW642444", "type": "DRUG" }, { "name": "tiotropium bromide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 846, "start_date": "2011-03-01", "completion_date": "2012-04-24", "has_results": true, "last_update_posted_date": "2018-01-24", "last_synced_at": "2026-09-04T00:30:18.342Z", "location_count": 19, "location_summary": "Birmingham, Alabama • San Diego, California • DeLand, Florida + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01316900" }, { "nct_id": "NCT05292053", "title": "Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Copd" ], "interventions": [ { "name": "TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2022-07-01", "completion_date": "2025-02-09", "has_results": true, "last_update_posted_date": "2025-11-21", "last_synced_at": "2026-09-04T00:30:18.342Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05292053" }, { "nct_id": "NCT01627327", "title": "Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "fluticasone furoate/vilanterol 100/25mcg", "type": "DRUG" }, { "name": "tiotropium bromide 18mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 623, "start_date": "2012-04-01", "completion_date": "2012-12-21", "has_results": true, "last_update_posted_date": "2017-11-09", "last_synced_at": "2026-09-04T00:30:18.342Z", "location_count": 11, "location_summary": "Newport Beach, California • Coeur d'Alene, Idaho • Charlotte, North Carolina + 8 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Coeur d'Alene", "state": "Idaho" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Medford", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01627327" }, { "nct_id": "NCT01323634", "title": "Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg", "type": "DRUG" }, { "name": "Fluticasone Propionate 250mcg/ salmeterol 50mcg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 519, "start_date": "2011-03-18", "completion_date": "2011-12-14", "has_results": true, "last_update_posted_date": "2017-11-08", "last_synced_at": "2026-09-04T00:30:18.342Z", "location_count": 12, "location_summary": "Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Madisonville", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01323634" }, { "nct_id": "NCT01323621", "title": "Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg", "type": "DRUG" }, { "name": "Fluticasone Propionate 250mcg / salmeterol 50mcg", "type": "DRUG" }, { "name": "Double-dummy placebo", "type": "DRUG" }, { "name": "Salbutamol as needed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 512, "start_date": "2011-03-18", "completion_date": "2012-01-24", "has_results": true, "last_update_posted_date": "2018-02-15", "last_synced_at": "2026-09-04T00:30:18.342Z", "location_count": 13, "location_summary": "Jasper, Alabama • Riverside, California • DeLand, Florida + 10 more", "locations": [ { "city": "Jasper", "state": "Alabama" }, { "city": "Riverside", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Coeur d'Alene", "state": "Idaho" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01323621" } ] }